{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T07:00:49Z","timestamp":1785308449354,"version":"3.55.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Intravenous phentolamine mesylate and furosemide are widely administered via infusion pumps to treat severe pediatric critical illnesses. Their off-label concurrent use lacks reliable physicochemical compatibility and stability data, bringing potential medication safety risks. This study aimed to evaluate the 8-hour compatibility and stability of the two drugs mixed in syringes under simulated clinical\n                      <jats:italic>in vitro<\/jats:italic>\n                      conditions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Two clinically relevant concentration gradients were set for testing: phentolamine mesylate at 0.1 and 0.5\u2005mg\u00b7mL\u207b\n                      <jats:sup>1<\/jats:sup>\n                      , and furosemide at 0.5 and 1.0\u2005mg\u00b7mL\u207b\n                      <jats:sup>1<\/jats:sup>\n                      . Drug admixtures were prepared by dilute mixing using either 0.9% sodium chloride injection (0.9% NS) or 5% glucose injection (5% GS). All solutions were stored at room temperature (25\u2009\u00b1\u20091\u2005\u00b0C) under natural light and sampled at 0, 2, 4, 6 and 8\u2005h. Physicochemical indicators including appearance, pH value, insoluble particles and relative drug content were determined to assess mixture stability.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Throughout the 8-hour observation period, all mixed solutions remained clear and colorless without precipitation, turbidity, or discoloration. The pH values remained stable with a fluctuation range within \u00b10.4 units. The number of insoluble particles complied with the standards specified in the 2020 edition of the Chinese Pharmacopoeia. Moreover, the relative percentage content of both phentolamine mesylate and furosemide remained above 95% at all time points.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Under\n                      <jats:italic>in vitro<\/jats:italic>\n                      conditions at room temperature (25\u2009\u00b1\u20091\u2005\u00b0C) with natural light exposure, admixtures of phentolamine mesylate (0.1 or 0.5\u2005mg\u00b7mL\u207b\n                      <jats:sup>1<\/jats:sup>\n                      ) and furosemide injection (0.5 or 1.0\u2005mg\u00b7mL\u207b\n                      <jats:sup>1<\/jats:sup>\n                      ) prepared via dilute mixing in either 0.9% NS or 5% GS remained physicochemically stable for up to 8\u2005h. The findings are only valid for the specific experimental parameters in this work and cannot be generalized to routine off-label combined administration in pediatric critical care.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2026.1893184","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:03:44Z","timestamp":1785305024000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Stability and compatibility of phentolamine mesylate combined with furosemide in common infusion solutions for pediatric critical care"],"prefix":"10.3389","volume":"14","author":[{"given":"Baoxia","family":"Fang","sequence":"first","affiliation":[{"name":"Sinopharm Dongfeng General Hospital, Hubei University of Medicine","place":["Shiyan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiling","family":"Shang","sequence":"additional","affiliation":[{"name":"Renmin Hospital, Hubei University of Medicine","place":["Shiyan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuchao","family":"Chen","sequence":"additional","affiliation":[{"name":"Sinopharm Dongfeng General Hospital, Hubei University of Medicine","place":["Shiyan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Liu","sequence":"additional","affiliation":[{"name":"Renmin Hospital, Hubei University of Medicine","place":["Shiyan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Liu","sequence":"additional","affiliation":[{"name":"Sinopharm Dongfeng General Hospital, Hubei University of Medicine","place":["Shiyan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1198356","DOI":"10.3389\/fpubh.2023.1198356","article-title":"Trends, influencing factors and prediction analysis of under-five and maternal mortality rates in China from 1991 to 2020","volume":"11","author":"Zhang","year":"2023","journal-title":"Front Public Health"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e2441821","DOI":"10.1001\/jamanetworkopen.2024.41821","article-title":"Outpatient antibiotic use and treatment failure among children with pneumonia","volume":"7","author":"Shapiro","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1141366","DOI":"10.3389\/fped.2023.1141366","article-title":"Survival status and predictors of mortality from severe community-acquired pneumonia among under-five children admitted at debre tabor comprehensive specialized hospital: a prospective cohort study","volume":"11","author":"Kassaw","year":"2023","journal-title":"Front Pediatr"},{"key":"B4","doi-asserted-by":"publisher","first-page":"345","DOI":"10.12173\/j.issn.1008-049X.202311231","article-title":"Effects of beta-blockers for congestive heart failure in pediatric patients: meta-analysis","volume":"27","author":"Wang","year":"2024","journal-title":"China Pharm"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.3969\/j.issn.1673-5293.2019.12.024","article-title":"The observation on effect of phentolamine combined with furosemide to treat pediatric pneumonia with cardiac insufficiency","volume":"30","author":"Yu","year":"2019","journal-title":"Chin J Woman Child Health Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1063795","DOI":"10.3389\/fped.2023.1063795","article-title":"Case report: catecholamine cardiomyopathy in children with neuroblastoma","volume":"11","author":"Xu","year":"2023","journal-title":"Front Pediatr"},{"key":"B7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.21037\/tp-21-516","article-title":"Efficacy of phentolamine combined with ambroxol aerosol inhalation in the treatment of pediatric severe pneumonia and its effect on serum IL-10 and CRP levels","volume":"11","author":"Li","year":"2022","journal-title":"Transl Pediatr"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.3892\/etm.2017.4104","article-title":"Therapeutic efficacy of phentolamine in the management of severe hand, foot and mouth disease combined with pulmonary edema","volume":"13","author":"Yan","year":"2017","journal-title":"Exp Ther Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"8821126","DOI":"10.1155\/2021\/8821126","article-title":"A fast and validated HPLC method for simultaneous determination of dopamine, dobutamine, phentolamine, furosemide, and aminophylline in infusion samples and injection formulations","volume":"2021","author":"Chen","year":"2021","journal-title":"J Anal Methods Chem"},{"key":"B10","doi-asserted-by":"publisher","first-page":"479","DOI":"10.5863\/1551-6776-24.6.479","article-title":"Evaluation of incompatible coadministration of continuous intravenous infusions in a pediatric\/neonatal intensive care unit","volume":"24","author":"H\u00e4ni","year":"2019","journal-title":"J Pediatr Pharmacol Ther"},{"key":"B11","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12887-019-1499-2","article-title":"Drug related problems in the neonatal intensive care unit: incidence, characterization and clinical relevance","volume":"19","author":"Leopoldino","year":"2019","journal-title":"BMC Pediatr"},{"key":"B12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s40360-018-0265-7","article-title":"Potential drug incompatibilities in the neonatal intensive care unit: a network analysis approach","volume":"19","author":"Leopoldino","year":"2018","journal-title":"BMC Pharmacol Toxicol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1023\/a:1008780126781","article-title":"Evaluation of physicochemical incompatibilities during parenteral drug administration in a paediatric intensive care unit","volume":"22","author":"Gikic","year":"2000","journal-title":"Pharm World Sci"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e609","DOI":"10.1542\/peds.2008-3080","article-title":"Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events","volume":"123","author":"Bradley","year":"2009","journal-title":"Pediatrics"},{"key":"B15","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1365-2710.2010.01160.x","article-title":"Stability and compatibility of doxofylline with phentolamine mesilate in 0\u00b79% sodium chloride or 5% dextrose injection for intravenous infusion","volume":"36","author":"Xu","year":"2011","journal-title":"J Clin Pharm Ther"},{"key":"B16","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1136\/ejhpharm-2017-001264","article-title":"Furosemide ethanol-free oral solutions for paediatric use: formulation, HPLC method and stability study","volume":"25","author":"Zah\u00e1lka","year":"2018","journal-title":"Eur J Hosp Pharm"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.2146\/ajhp170111","article-title":"Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration","volume":"74","author":"Du Repaire","year":"2017","journal-title":"Am J Health Syst Pharm"},{"key":"B18","first-page":"522","article-title":"Intravenous physical compatibility of heparin sodium and furosemide","volume":"26","author":"Maktabi","year":"2022","journal-title":"Int J Pharm Compound"},{"key":"B19","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/2110-5820-2-28","article-title":"Impact of physical incompatibility on drug mass flow rates: example of furosemide-midazolam incompatibility","volume":"2","author":"Foinard","year":"2012","journal-title":"Ann Intensive Care"},{"key":"B20","first-page":"420","article-title":"Stability assessment of 10 active pharmaceutical ingredients compounded in SyrSpend SF","volume":"19","author":"Geiger","year":"2015","journal-title":"Int J Pharm Compound"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1093\/ajhp\/zxad232","article-title":"Physical compatibility of sulbactam\/durlobactam with select intravenous drugs during simulated Y-site administration","volume":"81","author":"Ruiz","year":"2024","journal-title":"Am J Health Syst Pharm"},{"key":"B22","doi-asserted-by":"publisher","first-page":"20220002","DOI":"10.1515\/pthp-2022-0002","article-title":"Y-site compatibility of intravenous medications commonly used in intensive care units: laboratory tests on 75 mixtures involving nine main drugs","volume":"7","author":"Ayari","year":"2022","journal-title":"Pharm Technol Hosp Pharm"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/s00431-020-03854-7","article-title":"Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units","volume":"180","author":"De Basagoiti","year":"2021","journal-title":"Eur J Pediatr"},{"key":"B24","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3390\/ph12020067","article-title":"Investigations of physical compatibilities of commonly used intravenous medications with and without parenteral nutrition in pediatric cardiovascular intensive care unit patients","volume":"12","author":"Greenhill","year":"2019","journal-title":"Pharmaceuticals"},{"key":"B25","first-page":"52","article-title":"Physical compatibility of cefiderocol with selected intravenous drugs during simulated Y-site administration","volume":"25","author":"Lu","year":"2021","journal-title":"Int J Pharm Compound"},{"key":"B26","doi-asserted-by":"publisher","first-page":"20200011","DOI":"10.1515\/pthp-2020-0011","article-title":"Compatibility of injectable posaconazole with drugs commonly used in a hematology care unit","volume":"5","author":"Polo","year":"2020","journal-title":"Pharm Technol Hosp Pharm"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1093\/ajhp\/zxaa296","article-title":"Physical compatibility of milrinone 1 mg\/mL with select cardiovascular medications during simulated Y-site administration","volume":"77","author":"Griffith","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"B28","doi-asserted-by":"publisher","first-page":"156","DOI":"10.5863\/1551-6776-13.3.156","article-title":"Physical compatibility of ibuprofen lysine injection with selected drugs during simulated Y-site injection","volume":"13","author":"Holt","year":"2008","journal-title":"J Pediatr Pharmacol Ther"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.2146\/ajhp170839","article-title":"Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration","volume":"75","author":"Asempa","year":"2018","journal-title":"Am J Health Syst Pharm"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.2146\/ajhp170123","article-title":"Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration","volume":"75","author":"Monogue","year":"2018","journal-title":"Am J Health Syst Pharm"},{"key":"B31","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12911-020-01231-w","article-title":"Towards more efficient use of intravenous lumens in multi-infusion settings: development and evaluation of a multiplex infusion scheduling algorithm","volume":"20","author":"Doesburg","year":"2020","journal-title":"BMC Med Inform Decis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s00228-018-2602-6","article-title":"Drug incompatibilities in intravenous therapy: evaluation and proposition of preventive tools in intensive care and hematology units","volume":"75","author":"Maison","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1007\/s00228-021-03112-1","article-title":"Strategies to prevent drug incompatibility during simultaneous multi-drug infusion in intensive care units: a literature review","volume":"77","author":"N\u00e9grier","year":"2021","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1893184\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:03:48Z","timestamp":1785305028000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1893184\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":33,"alternative-id":["10.3389\/fped.2026.1893184"],"URL":"https:\/\/doi.org\/10.3389\/fped.2026.1893184","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"article-number":"1893184"}}